Brief: UCB Says Its KYGEVVI Recommended For Approval In EU
30/01/2026 12:09
Jan 30 (Reuters) - Ucb SA UCB.BR: KYGEVVI[®] (DOXECITINE AND DOXRIBTIMINE) RECOMMENDED FOR APPROVAL IN THE EUROPEAN UNION AS TREATMENT FOR THYMIDINE KINASE 2 DEFICIENCY (TK2D) FINAL EUROPEAN COMMISSION (EC) DECISION IS ANTICIPATED IN Q2 2026 Source text Further company coverage: UCB.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside